Abstracts tagged "calcinosis"

Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Yao-Wei Zou, Ying Yang, Zhi-Ming Ouyang, Ran Shi, Tao Wu, Kui-Min Yang, Jian-Da Ma and Lie Dai, Department of Rheumatology and Immunology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic)
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…
Abstract Number: 2145 • ACR Convergence 2025
EOS® Imaging System Is a Novel, Rapid, Safe, and Effective Technique To Detect And Assess Calcinosis In JDM
Jessica Perfetto¹, Ciara Maguire², Carli Needle³, Shailee Lala⁴, Vikash Oza² and Philip Kahn⁵, ¹Pediatric Rheumatology, Hassenfeld Children's Hospital at NYU Langone, New York, ²Pediatric Dermatology, Ronald O Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, ³NYU Grossman School of Medicine, New York, ⁴Department of Radiology, NYU Grossman School of Medicine, New York, ⁵Pediatric Rheumatology, Hassenfeld Children’s Hospital at NYU Langone, New York
Background/Purpose: Calcinosis, reported in up to 47% of children with juvenile dermatomyositis (JDM), can cause significant morbidity, including ulceration, infection, and contractures. Given associations of…
Abstract Number: 1967 • ACR Convergence 2025
Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging
Saahil Sachdeva¹, Briana Cervantes², Lisa Rider³ and Adam Schiffenbauer⁴, ¹NIEHS/NIBIB/NIH, Danville, CA, ²Department of Emergency Medicine, Norfolk, VA, ³National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁴National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by chronic muscle and skin inflammation. One potential complication of DM is calcinosis, the heterotopic calcification…
Abstract Number: 1581 • ACR Convergence 2025
The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
Marie-Elise Martel¹, Zélie Guitton², Aurélien Chepy¹, SEBASTIEN SANGES³, Eric Hachulla⁴, David Launay¹ and Vincent Sobanski⁵, ¹Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, ²CH Lens, Lens, France, ³Medecine Interne CHRU Lille, Lille, France, ⁴University of Lille, LILLE, France, ⁵Université de Lille, Lille, France
Background/Purpose: Calcinosis is a high-burden, key manifestation of systemic sclerosis (SSc), with a challenging therapeutic management. Yet, its precise prevalence and association with SSc charcateristics…
Abstract Number: 1214 • ACR Convergence 2025
Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis
Sangmee Bae¹, Srijana Davuluri², Brian Lee³, Sean Lim⁴, Daniela Markovic⁵, Lorinda Chung², David Fiorentino⁶ and Christina Charles-Schoeman⁷, ¹UCLA Rheumatology, Los Angeles, CA, ²Stanford University, Stanford, CA, ³Stanford University, Stanford, ⁴Stanford University, Palo Alto, ⁵UCLA, Los Angeles, ⁶Department of Dermatology, Stanford University Medical Center, Stanford, CA, ⁷UCLA Medical Center, Santa Monica, CA
Background/Purpose: Calcinosis is a feature seen in systemic sclerosis (SSc) and dermatomyositis (DM) that leads to significant morbidity and poor quality of life. Inflammatory vasculopathy…
Abstract Number: 1194 • ACR Convergence 2025
Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
Antonia Valenzuela¹, Nicolás González², José Rojas³, Martin Fuentes³, Srijana Davuluri⁴, Brian Lee⁵, David Fiorentino⁶ and Lorinda Chung⁴, ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ³Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ⁴Stanford University, Stanford, CA, ⁵Stanford University, Stanford, ⁶Department of Dermatology, Stanford University Medical Center, Stanford, CA
Background/Purpose: Calcinosis is a painful, debilitating manifestation in connective tissue diseases. Recent findings suggest a link between proton pump inhibitor (PPI) use and calcinosis in…
Abstract Number: 0701 • ACR Convergence 2025
Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
Maximiliano Diaz Menindez¹, Simran Ravindra Nimal², Michael Pham², Caroyln Harvey³, Leroy W. Griffing² and Vivek Nagaraja², ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Scottsdale, AZ, ³Mayo Clinic, Phoenix, AZ
Background/Purpose: Calcinosis is a vexing manifestation in patients with systemic sclerosis (SSc) with a variable prevalence among cohorts. Up to 86% of calcinosis cases are…
Abstract Number: 0674 • ACR Convergence 2025
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Ian Odell¹, Crystal Cheung¹, Megan Wu², Stephanie Perez³, Agrani Dixit⁴, Cassandra van Horn³, Muhammad Hamdan⁵, Baran Gunes⁶, Sophia Kujawski⁷, Hyojeong Lee³, Annie Wang³, Denise Esserman⁸, Michael Zamani⁹, F. Perry Wilson³, John Onofrey³, Xenophon Papademetris³ and Monique Hinchcliff¹⁰, ¹Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, Greenville, ³Yale University School of Medicine, New Haven, ⁴Yale School of Medicine, New Haven, CT, ⁵Yale University School of Medicine, Mansfield, ⁶Yale University School of Medicine, Pompton Plains, NJ, ⁷The George Washington University, New Haven, CT, ⁸Yale University School of Public Health, New Haven, ⁹Independent Statistician, Washington D.C., ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…
Abstract Number: 0865 • ACR Convergence 2025
Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin
Cassie Parks¹, York Wang¹, Lisa Christopher-Stine², Jemima Albayda², Joel Sunshine³, Shira Ziegler¹ and Chris Mecoli¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Calcinosis cutis affects up to 20% of adults with dermatomyositis (DM), causing significant morbidity including recurrent infections, incapacitating pain, and functional impairment. Current management…
Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…
Abstract Number: 2069 • ACR Convergence 2024
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Lovely Kumari¹, VISHNU KONERU², subin Philip¹, sai Kumar Dunga³, Mamatha gorijavulu⁴, Aishwarya Gopal⁵, Christina Mariaselvam⁶, Molly Thabah⁷, Vir Singh Negi⁸ and Chengappa Kavadichanda⁹, ¹JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, ²JIPMER,PUDUCHERRY, PUDUCHERRY, India, ³JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, ⁴JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶JIPMER, Puducherry, Puducherry, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁸AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, ⁹Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India
Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
Abstract Number: 2688 • ACR Convergence 2024
HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis
Sara Faghihi-Kashani¹, srijana davluri², Kamini Kuchinad³, Zuoming deng⁴, Faiza Naz⁴, Stefania Dell'Orso⁴, Zsuzsanna McMahan⁵, Laura Hummers⁶, Daniel Kastner⁷, Fredrick Wigley³, david fiorentino⁸, Christian Lood⁹, Ami Shah¹⁰, Lorinda Chung¹¹ and Pravitt Gourh⁴, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, Sunnyvale, CA, ³Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁷National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, ⁸Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ⁹Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, ¹⁰Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ¹¹Stanford University, Woodside, CA
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…
Abstract Number: 1525 • ACR Convergence 2023
Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis
Alison Fernandes, Ashraf El-Meanawy and ME Csuka, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcinosis is a common complication of systemic sclerosis (SSc), though effective treatment options are limited. Of the several medical therapies that have been employed…
Abstract Number: 2360 • ACR Convergence 2023
Systemic Sclerosis Macrophages Stimulate Calcinosis in Adipose Derived Mesenchymal Stem Cells via the Activin a Pathway
Tamara Searle¹, Ujvalla Kalluri¹, Sonia Ahmad², Bahja Ahmed Abdi¹, Sandra Lopez¹, Shiwen Xu¹, Teresa Collins¹, Jennifer Cross³, George Martin⁴, Henry Lopez⁵, Clayton Yates⁶ and Richard Stratton¹, ¹University College London, London, United Kingdom, ²Holy Family Red Crescent Medical College, Dhaka, Bangladesh, ³Aurinia Pharmaceuticals Inc., Rockford, MD, ⁴Riptide Bioscience Inc., Bethesda, MD, ⁵Riptide Bioscience Inc., Valejo, CA, ⁶Tuskegee University, Tuskegee, AL
Background/Purpose: Calcinosis may result from localised trans-differentiation of tissue resident stem cells in the subcutaneous layer of affected skin in systemic sclerosis (SSc), as a…
Abstract Number: 0284 • ACR Convergence 2023
Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases
Michele Diomedi¹, Federico Fattorini¹, Simone Barsotti², Elenia Laurino¹, Chiara Cardelli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare systemic autoimmune disorders, with a pleiotropic clinical picture, specifically characterized from the inflammatory involvement of striate muscles. Calcinosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].